MedWatch

The Medwatch panel: Creating future biotech success stories

Future Danish biotech success stories should be created through more advantageous tax conditions, says ALK’s CEO, while Lundbeck’s executive would like to see a more aggresive public investment policy, for example a public investment fund. Strategic partnerships and less attendance to “the law of Jante” are among the other possible solutions identified by this week’s Medwatch panel.

A lack of capital is a recurrent issue when it comes to naming the greatest challenges for the Danish biotech industry. This week the members of the Medwatch panel offer their opinions on how to solve that problem.

How do we ensure that Danish biotech companies do not succumb to a lack of capital? And do you - the major players in the industry - do enough to share your knowledge and, for example, add risk capital?

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier